Sentence examples for overt progression from inspiring English sources

There is an emerging consensus to treat MDS patients with azacitidine for a minimum of 6 cycles before evaluating response unless overt progression to AML or unacceptable toxicity occurs.

Only patients with progressive disease (PD) were treated; those with residual disease following cytokine therapy were observed until overt progression as it is clear that long periods of progression-free survival can be observed in the presence of metastatic disease and sometimes spontaneous regressions can be seen (Oliver et al, 1988).

In 23 of the 34 patients, the brain was the predominant site of disease at entry to the study; however, only 17 out of 34 (50%) had overt progression in the brain and/or neurological symptoms at entry, other patients having more significant systemic progression with largely stable brain disease.

However, NK cell defects have been identified in treatment-naïve patients before overt progression to disease or at the time of diagnosis, demonstrating that the defects are not solely treatment related or the result of chronic inflammation from long-standing disease [ 59, 71].

However, recent studies have documented NK cell defects in treatment-naïve patients before overt progression to disease or at the time of diagnosis, demonstrating that the defects are not solely treatment-related or the result of chronic inflammation from long-standing disease [ 32, 33].

An early study in pediatric SLE patients was particularly informative since it demonstrated low numbers of peripheral NK cells and defective cytolysis (on a single cell level) at diagnosis or even prior to overt progression to SLE in a subset of patients [ 71].

We next examined spontaneous EPSCs, which have been shown previously to have a progressive decrease in frequency in MSNs of R6/2 and R6/1 mice with overt phenotype progression (Cepeda et al., 2003; Rossi et al., 2006).

Two patients received only one cycle each, owing to overt disease progression.

All patients were treated initially with oral gefitinib at a dose of 250 mg/day, which was continued until either a radiographic tumor or overt clinical progression was observed.

Thus, alternative schedules and dosages seem safe and without loss of efficacy, and receiving the drug regularly and continuously until overt clinical progression occurs is likely more relevant than the absolute dosage per day or number of days per cycle.

There is great interest in exploiting CTCs as a window on the molecular state of a tumor, since understanding the evolutionary path of a cancer may predict resistance before overt clinical progression, potentially allowing for the pre-emptive selection of a more effective therapy.